Paper41226440
The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research.
Grigoreva TA and 4 others. Int J Mol Sci, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research. Papers, record 41226440. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41226440
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Animals |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 23-13-00344 | Russian Science Foundation | PubMed |
Source PubMed
References153
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9137537 | Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP. | Cancer Chemother Pharmacol | 1997 | https://conductscience.org/library/papers/9137537 | PubMed |
| 2 | 36224343 | Molecular targeted therapy for anticancer treatment. | Exp Mol Med | 2022 | https://conductscience.org/library/papers/36224343 | PubMed |
| 3 | 38154263 | Mechanical effects modulate drug resistance in MCF-7-derived organoids: Insights into the wnt/β-catenin pathway. | Biochem Biophys Res Commun | 2024 | https://conductscience.org/library/papers/38154263 | PubMed |
| 4 | 25760096 | Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. | Mol Med Rep | 2015 | https://conductscience.org/library/papers/25760096 | PubMed |
| 5 | 38608058 | A comprehensive exploration of twist1 to identify a biomarker for tumor immunity and prognosis in pan-cancer. | Medicine (Baltimore) | 2024 | https://conductscience.org/library/papers/38608058 | PubMed |
| 6 | 39175042 | Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib). | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/39175042 | PubMed |
| 7 | 22179686 | Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. | Int J Oncol | 2012 | https://conductscience.org/library/papers/22179686 | PubMed |
| 8 | 38381934 | Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis. | Br J Surg | 2024 | https://conductscience.org/library/papers/38381934 | PubMed |
| 9 | 34830082 | 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34830082 | PubMed |
| 10 | 33046798 | Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. | Oncogene | 2020 | https://conductscience.org/library/papers/33046798 | PubMed |
| 11 | 30031797 | Molecular targeted therapy: Treating cancer with specificity. | Eur J Pharmacol | 2018 | https://conductscience.org/library/papers/30031797 | PubMed |
| 12 | 32486365 | Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32486365 | PubMed |
| 13 | 29410625 | Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/29410625 | PubMed |
| 14 | 38737455 | Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance. | Cell Mol Bioeng | 2024 | https://conductscience.org/library/papers/38737455 | PubMed |
| 15 | 24126575 | Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. | Int J Oncol | 2013 | https://conductscience.org/library/papers/24126575 | PubMed |
| 16 | 31133756 | Mitochondrial metabolism promotes adaptation to proteotoxic stress. | Nat Chem Biol | 2019 | https://conductscience.org/library/papers/31133756 | PubMed |
| 17 | 20512087 | The establishment and characterization of adriamycin-resistant cell lines derived from Saos-2. | Med Sci Monit | 2010 | https://conductscience.org/library/papers/20512087 | PubMed |
| 18 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 19 | 25566959 | Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. | Tumour Biol | 2015 | https://conductscience.org/library/papers/25566959 | PubMed |
| 20 | 21150160 | Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. | Gynecol Obstet Invest | 2011 | https://conductscience.org/library/papers/21150160 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42595339 | Polyphyllin I Orchestrates Autophagy to Reprogram the Tumour Immune Microenvironment and Abrogate Cisplatin Resistance in Non-Small Cell Lung Cancer. | Clin Exp Pharmacol Physiol | 2026 | https://conductscience.org/library/papers/42595339 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41226440
GET https://conductscience.org/api/papers/v1/41226440/references?page=2